Ken Griffin Sage Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $937,388 - $1.59 Million	88,600 Added 676.34%	101,700 $1.1 Million
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $1.08 Million - $1.56 Million	-57,800 Reduced 81.52%	13,100 $245,000
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $716,490 - $932,694	-41,900 Reduced 37.15%	70,900 $1.54 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $1.2 Million - $3.52 Million	71,800 Added 175.12%	112,800 $2.32 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $613,815 - $899,054	15,100 Added 58.3%	41,000 $1.93 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $1.83 Million - $2.29 Million	-49,100 Reduced 65.47%	25,900 $1.09 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $16,100 - $21,805	-500 Reduced 0.66%	75,000 $2.86 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $739,212 - $990,883	22,900 Added 43.54%	75,500 $2.96 Million

218

46.4M

847K

188K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.